10-K: Adagio Medical Faces Going Concern Amidst Losses, Advances VT Ablation

Adagio Medical Holdings, Inc. reported recurring net losses and a going concern warning, despite advancing its vCLAS Cryoablation System with Breakthrough Device Designation and positive clinical trial results.

Summary

• Adagio Medical Holdings, Inc. (ADGM) is a medical device company developing Ultra-Low Temperature Ablation (ULTA) technology for cardiac arrhythmias, primarily Ventricular Tachycardia (VT).
• The company has incurred net losses in every period since its inception in 2011, with an accumulated deficit of $95.6 million as of December 31, 2025.
• Net loss for the fiscal year ended December 31, 2025, was $25.1 million.
• Management has raised substantial doubt about the company's ability to continue as a going concern, with existing cash and cash equivalents of $17.1 million expected to fund operations only into the third quarter of 2026.
• The vCLAS Cryoablation System received Breakthrough Device Designation from the FDA in April 2025 for drug-refractory, recurrent, sustained monomorphic VT.
• Enrollment in the FULCRUM-VT Pivotal FDA Investigational Device Exemption (IDE) study for vCLAS was completed in October 2025, involving 209 patients across 19 centers in the U.S. and Canada.
• Preliminary acute safety and efficacy results from FULCRUM-VT showed 97.4% acute clinical success and 96.7% elimination of clinically-relevant VTs, with a 2.4% major adverse event rate, including four (1.9%) peri-procedural deaths, one (0.5%) definitely device-related.
• The company paused its limited European commercial launch of the vCLAS catheter and significantly reduced commercial activities in February 2025 as part of a corporate prioritization initiative, resulting in nil revenue for FY 2025.
• A 2025 Private Placement closed in October 2025, raising approximately $19 million in gross proceeds, with potential for up to $31 million more from Milestone Warrants.
• The company is developing a next-generation ULTA technology for VT, which has completed its design phase, and Pulsed Field Cryoablation (PFCA) technology.
• The global market for electrophysiology (EP) devices was approximately $14 billion in 2025, projected to grow to over $33 billion by 2033, with VT ablation representing a large, underserved segment.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with significant caution. While clinical progress and regulatory designations for the vCLAS system are positive, the explicit 'going concern' warning, recurring losses, nil revenue in 2025, and substantial impairment charges in 2024 highlight severe financial instability and high operational risk.

Positives

• The vCLAS Cryoablation System received Breakthrough Device Designation from the FDA in April 2025, potentially accelerating development and review.
• Enrollment in the FULCRUM-VT Pivotal FDA IDE study was completed in October 2025, a significant milestone for regulatory approval.
• Preliminary acute safety and efficacy results from FULCRUM-VT are promising, showing 97.4% acute clinical success and 96.7% elimination of clinically-relevant VTs.
• The vCLAS Cryoablation System for VT has obtained European CE Mark approval, supported by positive CRYOCURE-VT trial results (0% major adverse events, 94% acute procedural success, 60% freedom from sustained VT, and 81% freedom from ICD shock at six months).
• CMS approved the vCLAS catheter and associated ablation services for Medicare coverage in July 2023, which was confirmed for the FULCRUM-VT pivotal study in September 2024.
• The company is developing a next-generation ULTA technology for VT with improved usability and a single-freeze protocol, having completed its design phase.
• Development of Pulsed Field Cryoablation (PFCA) technology offers a dual-therapy platform with potential advantages.
• The total addressable global market for VT ablation is estimated at $5.8 billion, indicating a substantial growth opportunity for purpose-built solutions.

Negatives

• The company has incurred net losses in every period since its inception in 2011, with an accumulated deficit of $95.6 million as of December 31, 2025.
• A net loss of $25.1 million was reported for the fiscal year ended December 31, 2025.
• Management has raised substantial doubt about the company's ability to continue as a going concern, with current cash expected to fund operations only into Q3 2026.
• Revenue for the year ended December 31, 2025, was nil, due to a strategic pause in European commercial activities and an inventory buyback.
• Significant impairment charges totaling $49.2 million were recorded in 2024 for goodwill ($30.3 million) and intangible assets ($18.9 million), driven by a sustained decline in share price and market capitalization.
• The FULCRUM-VT trial reported a 2.4% rate of major adverse events, including four (1.9%) peri-procedural deaths, with one (0.5%) adjudicated as definitely related to the investigational device.
• A previous serious adverse event (patient death) in October 2021 during the iCLAS IDE trial led to a six-month voluntary study pause and required corrective actions.

Risks

• Incurred net losses and financial conditions raise substantial doubt about the ability to continue as a going concern.
• Limited operating history and no history of commercializing products make future viability difficult to assess.
• May need to raise additional capital, which could cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies.
• Changes in business strategy or restructuring may increase costs or affect profitability/asset value.
• Growth and revenue prospects depend on accelerating commercialization, which is uncertain.
• Operating results may fluctuate significantly, making future results difficult to predict.
• No assurance of executing the business model or achieving market acceptance of products.
• The size of the markets for products may be smaller than estimated, limiting sales ability.
• Significant disruption in information technology systems or security incidents could adversely affect operations, lead to loss of confidential information, increased remediation costs, and reputational damage.
• May be unable to manage anticipated growth effectively, straining management, operational, and manufacturing systems.
• Acquisitions or strategic partnerships could increase capital requirements and disrupt operations.
• Inability to recruit and retain key executives and scientists may hinder goal achievement.
• Consolidation in the medical device industry could adversely affect revenue and results of operations.
• Unfavorable U.S. or global economic conditions could adversely affect capital raising and business.
• Incorrect estimates or judgments relating to critical accounting policies could cause stock decline.
• Unavailable or inoperable facilities could adversely affect business plans.
• Clinical trials may be unsuccessful, significantly delayed, or incomplete, harming the business.
• Planned trials may not establish an adequate safety or efficacy profile, affecting market acceptance.
• Failure to establish relationships with partners or an effective commercialization network may adversely affect product commercialization.
• Inadequate physician training and patient selection may negatively affect product outcomes.
• Failure to improve products or introduce new ones could harm prospects.
• Inability to establish manufacturing capacity could delay commercialization.
• Difficulties with third-party suppliers and manufacturers could harm the business.
• Products could have unknown defects or errors, leading to claims and affecting market adoption.
• Failure to obtain and maintain sufficient intellectual property (IP) protection or if scope is not broad enough, competitors could commercialize similar products.
• Changes in U.S. law relating to intellectual property may adversely impact the business.
• Inability to protect IP rights throughout the world could harm business prospects.
• Expensive, time-consuming IP lawsuits may prevent or delay efforts.
• Issued patents covering products could be found invalid or unenforceable if challenged.
• Failure to protect trade secrets could materially, adversely affect technology value.
• May be subject to claims challenging inventorship or ownership of patents and other IP.
• May not be able to protect and enforce trademarks and trade names or build name recognition.
• No assurances of obtaining necessary FDA approvals to market products in the United States.
• Subject to enforcement action for improper or off-label marketing or promotion.
• Disruptions at FDA, SEC, and other government agencies could hinder timely product development/commercialization.
• Adverse findings in post-marketing vigilance or regulatory audits could lead to suspension/withdrawal of certificates, recalls, and significant legal liability.
• Subject to enforcement action for marketing products under improper regulatory classifications in the EU.
• Subject to evolving data privacy and security laws; non-compliance could harm business.
• Failure to comply with broad and complex healthcare and other laws could lead to substantial penalties.
• Subject to anti-corruption, anti-bribery, and anti-money laundering laws; non-compliance can lead to fines and penalties.
• Employees, contractors, etc., may engage in misconduct or improper activities.
• Recently enacted and future legislation may increase difficulty/cost to commercialize products and affect prices.
• Risks associated with Convertible Securities Notes could adversely affect financial condition.
• Subject to risks relating to increased interest rates and adverse developments in credit markets.
• Ability to use Net Operating Loss (NOL) carryforwards and other tax attributes may be limited.
• A new 1% U.S. federal excise tax could be imposed on stock redemptions.
• Unanticipated tax laws or changes in tax rates/application may adversely impact results.
• Perceptive PIPE Investor has control over key decision-making due to majority voting power.
• Financial resources may be used in ways stockholders disagree with or that don't yield favorable returns.
• Status as an emerging growth company and smaller reporting company could make stock less attractive.
• Stock price may be volatile and decline regardless of operating performance.
• May be unable to maintain Nasdaq listing.
• An active trading market for common stock may not be sustained.
• Future sales of shares by existing stockholders could cause stock price to decline.
• Issuance of additional shares or equity securities would dilute ownership.
• Inaccurate or unfavorable research publication could decline common stock.
• Delaware law and Charter/Bylaws provisions could make merger/tender offer/proxy contest difficult.
• Delaware Court of Chancery as exclusive forum for disputes could limit stockholders' ability to obtain favorable judicial forum.

Future Outlook

The company plans to share the six-month results of the FULCRUM-VT trial in April 2026 at the Heart Rhythm 2026 Conference and intends to submit these results to support its application for FDA approval of the vCLAS Cryoablation System in the first half of 2026. It also expects to incur increasing costs as it continues to develop and commercialize its vCLAS platform and next-generation ULTA technology. The company anticipates continued operating losses and negative cash flows for at least the next several years and will require additional capital to fund future operations.

Management Comments

• We believe that our purpose-built solution has the potential to drive market growth in ablative treatment of the large, underserved VT patient population.
• Preliminary data suggest that our approach to treating VT offers a favorable combination of safety, acute and chronic effectiveness, compared to the current standard of care.
• We expect to incur increasing costs as we continue to devote substantially all of our resources towards the development and anticipated further commercialization of our main platform technology, vCLAS.
• We are actively pursuing strategies to mitigate these risks (going concern), however, there can be no assurance that these efforts will prove successful or that we will achieve our intended financial stability.
• Our future success is largely dependent on our ability to successfully develop and commercialize our pipeline products, which are based on innovative yet complex technologies.

Industry Context

StockSavvy.ai notes that Adagio Medical operates in the rapidly growing electrophysiology (EP) device market, which reached approximately $14 billion in 2025 and is projected to exceed $33 billion by 2033, driven by technological advancements like pulsed field ablation (PFA). The company's focus on ventricular tachycardia (VT) ablation addresses a significant, underserved segment of this market, where current radiofrequency (RF) ablation technologies are suboptimal. While the market is responsive to innovation, Adagio faces intense competition from established players like Biosense Webster, Abbott, Medtronic, and Boston Scientific, who are also exploring PFA for ventricular applications.

Comparison to Industry Standards

• Adagio's vCLAS Cryoablation System aims to overcome limitations of current RF ablation technology for VT, which typically offers limited lesion depth (5-6mm) and is attenuated by myocardial scar tissue, leading to an 11.5% serious complication rate.
• The company's ULTA technology is designed to create titratable, large, durable lesions exceeding 10 millimeters in depth, which is superior to the typical RF lesion depth and crucial for treating the thicker ventricular myocardium.
• Unlike RF ablation, ULTA's cryoadhesion provides catheter stability, and the lack of irrigation eliminates fluid overload risk, addressing key technical challenges and complications associated with standard RF procedures.
• The CRYOCURE-VT trial demonstrated a 0% rate of major adverse events, 94% acute procedural success, 60% freedom from sustained VT, and 81% freedom from ICD shock at six months, which compares favorably to the high complication rates and suboptimal outcomes often seen with existing VT ablation methods.
• Adagio's PFCA technology aims to combine ULTA and PFA benefits, potentially addressing PFA's limitations such as muscle and phrenic nerve capture and vasospasm, which are challenges for competitors applying PFA to ventricular ablations.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings that, if determined adversely, would individually or in the aggregate have a material adverse effect on its business, financial condition, and results of operations.

Related Party Transactions

• Incurred $0.4 million in 2025 for finance and accounting services and other general and administrative support services from Fjord Ventures, a company owned and operated by the company's former CEO.
• The Shared Services Agreement with Fjord Ventures was terminated on August 31, 2025, and a new agreement for human resources and payroll services became effective September 1, 2025.
• The company issued a $7.0 million Convertible Securities Note to Perceptive PIPE Investor, the controlling party, in exchange for their investment in Legacy Adagio's February 2024 Convertible Notes.
• Issued 4,372,607 common shares and 3,540,000 Base Warrants to Perceptive PIPE Investor to settle Bridge Financing Notes and accrued interest as part of the 2024 PIPE Financing.
• Issued 2,250,352 common shares and 1,905,069 Base Warrants to Perceptive PIPE Investor for an additional cash investment of $15.9 million in the 2024 PIPE Financing.
• Issued 2,190,496 2025 PIPE Pre-Funded Warrants and Milestone Warrants to Perceptive PIPE Investor for an aggregate purchase price of $4,250,000 in the 2025 PIPE Financing.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from future equity raises and potential decline in stock price due to ongoing losses and going concern warning. The Perceptive PIPE Investor holds significant control over key decision-making.
• **Employees**: The corporate prioritization initiative in February 2025, which included reduced commercial activities, could impact employee morale and lead to attrition beyond the intended number of employees. The company's ability to attract and retain skilled personnel is crucial for its success.
• **Customers (Hospitals/Physicians)**: The pause in European commercial activity means products are not currently available there. Future adoption in the U.S. depends on successful FDA approval, physician awareness, training, and perceived safety/effectiveness of the vCLAS system.
• **Creditors**: The company has $21.04 million in Convertible Securities Notes with a 13% interest rate, maturing in April 2028. The going concern warning indicates potential challenges in meeting future debt obligations without additional financing.
• **Suppliers**: The company relies on a limited number of third-party suppliers, including sole-source suppliers, for critical components. Disruptions in the global supply chain or quality issues could impact manufacturing and distribution.

Next Steps

• Share the six-month results of the FULCRUM-VT trial in April 2026 at the Heart Rhythm 2026 Conference.
• Submit the results of the FULCRUM-VT trial to support the application for FDA approval of the vCLAS Cryoablation System in the first half of 2026.
• Continue to develop the next-generation ULTA technology for VT, with the design phase already completed.
• Negotiate other cash equity or debt financing in the short-term to address going concern issues.
• Continue to pursue necessary regulatory approvals to launch commercially in the U.S. market.
• Execute cost-cutting measures to manage cash burn.

Key Dates

Recommendation

The company's explicit 'substantial doubt about its ability to continue as a going concern,' coupled with recurring net losses, nil revenue in 2025, and significant impairment charges in 2024, indicates severe financial distress. While clinical progress is noted, the fundamental financial instability and high operational risks outweigh these developments, making the stock a strong sell for seasoned investors.

Keywords

Ventricular Tachycardia, Cardiac Arrhythmias, Ablation Technology, Ultra-Low Temperature Ablation, ULTA, vCLAS Cryoablation System, Medical Device, Electrophysiology, FDA Breakthrough Device, Clinical Trials, FULCRUM-VT, Cryoablation, Pulsed Field Cryoablation, PFCA, SEC Filing, 10-K, Going Concern, Biotechnology, Healthcare